Detection of HIV for Self-Testing (R61/R33 Clinical Trial Not Allowed)

Funding Agency:
National Institutes of Health

The purpose of this Funding Opportunity Announcement (FOA) is to support collaborative, interdisciplinary early-stage research to inform the development of innovative rapid, sensitive, simple, and cost-effective diagnostic technologies that will enable HIV self-testing during the earliest phases of acute infection or during viral rebound.  


  • Letter of Intent Due Date(s): 30 days prior to the application due date
  • AIDS Application Due Date(s): March 17, 2021; March 17, 2022; March 17, 2023

PAR-21-070 Expiration Date March 18, 2023

Agency Website

Amount Description

Application budgets are limited to $300,000 in direct costs per year in the R61 phase and $500,000 in direct costs per year in the R33 phase. All F&A costs are excluded from this limit. Requested budgets should reflect the actual needs of the proposed project.

The scope of the proposed project should determine the project period. The maximum project period for an application submitted in response to this FOA cannot exceed five years. Applicants may request up to three years of support for the R61 phase, and up to two years of support for the R33 phase.

Funding Type





Engineering and Physical Sciences
Environmental & Life Sciences
Medical - Basic Science
Medical - Clinical Science
Medical - Translational

External Deadline

March 17, 2023